- Fedasz will focus on opening new markets for Evofem’s first – and only – in-class contraceptive, Phexxi® (lactic acid, citric acid and potassium bitartrate)
SAN DIEGO, April 11, 2022 /PRNewswire/ —Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as Chief Business Development Officer. At Evofem, Karina will oversee the company’s business development, product and pipeline portfolios, new business ventures and the advancement of access partnerships worldwide.
“Evofem is giving more women access to Phexxi, a hormone-free contraceptive, in the United States. We are now stepping up our efforts to enable women to access Phexxi outside of the United States,” said Saundra Pelletier, CEO of Evofem. “Karina’s decades of successful deal-making in our ever-growing global economy has already begun to help Evofem establish and build the partnerships that will allow Phexxi to access new markets around the world. .”
Fedasz has held various leadership positions in business development, operations, finance, and mergers and acquisitions. Earlier in her career, at JP Morgan, she entered into partnerships and transactions around the world as well as in various start-ups. These deals and partnerships have included nine-figure acquisitions and helped companies grow into multi-million dollar companies in less than three years. Fedasz is a graduate of UCLA and earned her MBA from Columbia Business School.
“Evofem offers the opportunity to work with a world-class team that helps women around the world stay in control of their reproductive health,” said Karina Fedasz, Business Development Manager. “Our strategy is clear and determined to open new markets for Phexxi outside of the United States”
Evofem will publish its results for the first quarter of 2022 on May 4, 2022.
About Phexxi® (lactic acid, citric acid and potassium bitartrate)
Phexxi® is an on-demand method of contraception used to prevent pregnancy. Phexxi is not effective when used after sex.
Important Safety Information
- Rare cases (0.36%) of bladder and kidney infections have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi.
- Contact your healthcare provider if you experience genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.
- Phexxi does not protect against sexually transmitted infections, including HIV.
For more information about Phexxi, talk to your healthcare provider and view the full product information at www.phexxi.com.
Please report side effects by contacting Evofem Biosciences free of charge at 1-833-EVFMBIO or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Intended for US residents only.
About Evofem Biosciences
Evofem Biosciences, Inc. (Nasdaq: EVFM) develops and markets innovative products to address the unmet sexual and reproductive health needs of women, including hormone-free, female-controlled contraception and protection against chlamydia and gonorrhea. The company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal contraceptive gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each sexual intercourse. Learn more about phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
This press release contains “forward-looking statements” within the meaning of the safe harbor for forward-looking statements contemplated by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including, without limitation, market and other conditions, the likelihood or ability to complete an out-of-state transaction United States, if regulatory approvals for marketing Phexxi outside of the US can be obtained, and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. . Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements or that could adversely affect the value of the assets and businesses of Evofem Biosciences are disclosed in the documents filed by the Company. with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 10, 2022. All forward-looking statements are expressly qualified in their entirety by these factors. The Company undertakes no obligation to update forward-looking statements, except as required by law.
Evofem Biosciences, Inc.
Evofem Biosciences, Inc.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-announces-karina-fedasz-as-companys-new-head-of-business-development-301522412.html
SOURCEEvofem Biosciences, Inc.
Company Codes: NASDAQ-NMS:EVFM